People with Parkinson's and Linked Clinical Trials

Find out more about our Linked Clinical Trials here.

Latest

Nerve Growth Factors and Parkinson's

For some considerable time CPT has been interested in nerve growth factors or 'neurotrophic' factors for Parkinson's. GDNF, CDNF and C-CDNF are three interesting candidates and our research work within this field continues with drive and urgency.
Emergency Medical Consultant Sketches to Raise Funds

Dr. Johnny Acheson is an Emergency Medical Consultant who is also living with Parkinson’s. Johnny has created sketches to fundraise and to educate about Parkinson’s and depict the humorous side of working in emergency medicine!
CPT ‘Raid Alpine’ Cycle Challenge becomes ‘Raid Local’!

Over 40 cyclists including Mike Tindall and Iain Balshaw, will set off independently on 28 June to tackle what would have been the toughest day on the 'Raid Alpine' ride - but instead, they'll be doing this around their local area!
3P - Post Doc Seminar - 25 June

Join Willemieke Kouwenhoven presenting on 'Vglut2 expression in dopamine neurons contributes to post-lesional striatal reinnervation' and Benoît Delignat-Lavaud discussing 'Mechanisms of somatodendric dopamine release and its contributions to post-lesional plasticity in a PD model”.

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut...
Science news

Read the latest Parkinson's science and research news here.
Trials - Repurposed Drugs

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Apply for Funding
The NAC Trial - the facts
Our story
Diabetes Drug Potential Disease-Modifying Therapy

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.
Alpha-synuclein and Parkinson's

Science news

Read the latest Parkinson's science and research news here. Read more

The Cure Collective

The Cure Collective is an opportunity to join like-minded individuals who are committed to help drive forward the quest to find a cure for Parkinson’s... Read more